All News

acr.quote_.png

'These Results Are Astonishing': What We Heard at ACR 2018

d RheumNow

"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.

Read Article
Gout.T2T.jpg

Treat-to-Target Strategy Cuts Mortality in Gout Patients

d RheumNow

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.

Read Article
ACR.2018.jpg

RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)

d Jack Cush, MD

This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups.  ACR 2018 highlights for me included:

Read Article
Data from >50K commercial and Medicare claims in RA patients shows the risk of VTE (DVT/PE) to No different comparing pts on tofacitinib vs TNFi (HR 1.33; 95% CI, 0.78-2.24). Abst L09 #ACR18 https://t.co/dafoEcl9pD

Links:

Dr. John Cush RheumNow ( View Tweet)

European Commission (EC) has approved a label update for Cosentyx (secukinumab), now allowing up to 300 mg dosing and also includes 24-week Xray data with inhibition of progression of joint damage in PsA https://t.co/S6d4XE75Ov

Links:

Dr. John Cush RheumNow ( View Tweet)

Matching the Reference Product is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi https://t.co/I8ydhjRlEL

Links:

Dr. John Cush RheumNow ( View Tweet)
Pegloticase is clearly our most important agent in Pts with high uric Acid burdens - it’s Achilles heal is immunogenicity- it’s vital to demonstrate whether this simple Rx is as good as it seems & Kudos to Alaska RHEUMS!!!! #ACR18 @GoutEducation @GoutandYou @HealioRheum https://t.co/MDvukRqCCx

Links:

Leonard Calabrese LCalabreseDO ( View Tweet)

Persistent Opioid Use Among Injured Workers’ Compensation Claimants https://t.co/hsmeB3uCCr

Links:

Daniel H Solomon DanielHSolomon ( View Tweet)

My top3 takeaways from #ACR18 1 PROs are a creative disruptive force and we need them in practice 2. JAKs should move up in our Rx priorities 3. IrAEs are an area of unmet educational need!! @HealioRheum @RheumNow @AWIRGROUP @rheumnews1 @psufka

Leonard Calabrese LCalabreseDO ( View Tweet)

Amazing Single Center study using Methotrexate (~15/wk) prophylaxis in 10 pts starting IV pegloticase for refractory gout - ALL responded; no immunogenicity, no rise in SUA. Another way of preventing interference by anti-PEG Abs. #ACR18, Abstr #1286 https://t.co/D4oWLNYaPE

Links:

Dr. John Cush RheumNow ( View Tweet)

Remember cutaneous lupus can be caused by medication. This changes our treatment. https://t.co/UQZE65aOFk

Links:

Michele Meltzer Rheumforall ( View Tweet)

ACR18 Insights >>> Published by Sjögrens Forum in Twitter: RT @KDAO2011: My top 3 takehomes from #ACR18 are: @rheumnow 1. ACR is thinking about leaving ABIM & join ABAI to form a new board certifyin… https://t.co/92qBxCVC6h #ACR18 #LucidQuest #followthepatient https://t.co/S1YHIXgoAS

Links:

Dr Timos Papagatsias _timos_ ( View Tweet)
#Methotrexate and #leflunomide survival in #patients with #psoriatic #arthritis Know more: https://t.co/kGlBeVFDzb https://t.co/1Nbq18Ai2O

Links:

Int J Clin Rheumatol rheumatol123 ( View Tweet)
Let's dig into today's announcement by @Potus & Dept of Health & Human Services to reduce #drugprices in Medicare Part B, from a rheumatology perspective. Read & retweet! First: what was it? It's an Advance Notice of Proposed Rulemaking (ANPRM). Link: https://t.co/ytxKpbElle 1/N

Links:

Angus Worthing MD AngusWorthing ( View Tweet)

This legitimately takes <1 min to do (see form in pic), and will help us avoid reimbursement cuts that would be disasterous for rheumatologists and our patiehts https://t.co/9FuirqGRod https://t.co/IxKeljB95O

Links:

Paul Sufka, MD psufka ( View Tweet)
New ACR guidelines for treatment management during pregnancy in patients with rheumatic diseases #ACR18 > AM https://t.co/RKhFHFJMt7
ARD & RMD Open ARD_BMJ ( View Tweet)
Patient safety is a critical part of Lilly's commitment to improving the rheumatoid arthritis treatment experience https://t.co/h4LD2oOOD3 #ACR18 https://t.co/ctXpr17Iar

Links:

Eli Lilly and Company LillyPad ( View Tweet)
It’s the psoriatic arthritis equivalent of watching Coltrane, Louis Armstrong and Duke Ellington on the same stage #ACR18 @RheumNow https://t.co/zGiJS6IDcS
David Liew drdavidliew ( View Tweet)
Comprehensive list of differential diagnosis of aortitis at vasculitis MOC session today. 1/3 of IgG4RD patients have vascular involvement (vasculitis+perivasc infiltrate) #ACR18 https://t.co/yu5ZO2dzCA
Didem Saygin, MD didemsayginmd ( View Tweet)
So proud of my dad for his hard work this year and his inspiring speech about the ACR's role in the future of medicine and politics! Also sincerely grateful for the opportunity to join in on so many of his trips and for always being so welcomed by the ACR. #ACR18 #Chicago https://t.co/fMQPLzMCcw
Clara Daikh CDaikh ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×